Background: Minoxidil is currently an approved treatment for androgenetic alopecia. Topical tretinoin can enhance skin absorption of minoxidil. Objective: This study has been done in order to determine the efficacy and safety of the solution of 0.5% minoxidil+0.05% tretinoin compared to 2% minoxidil in androgenetic alopecia in men. Patients and Methods: In a randomized, double-blind, parallel-g...

Objectives: To compare the safety and efficacy of MorrF (combination of Minoxidil [5%]+Finasteride [0.1%] lipid solution) with Minoxidil (5%) solution in adult male patients suffering from Androgenetic Alopecia (AGA). Background: AGA is one of the three most common forms of non-scarring alopecia with approximately 95% of hair loss cases in men and women. Fifty percent of men by age 50 years exh...

Rare cases of hypertrichosis have been associated with topically applied minoxidil. We present the first reported case in the Brazilian literature of generalized hypertrichosis affecting a 5-year-old child, following use of minoxidil 5%, 20 drops a day, for hair loss. The laboratory investigation excluded hyperandrogenism and thyroid dysfunction. Topical minoxidil should be used with caution in...

Background: Telogen effluvium is a self-limited, non-scarring disease that shows itself as a diffuse hair loss of the scalp that usually occurs 3 months after an acute illness. Theoretically, Minoxidil solution has been suggested as a treatment for this condition. In this study, we compared the efficacy of the minoxidil and an herbal drug containing urtica diocia, chamomilla, thymus vulgaris, e...

Six control dogs, six dogs treated with 1.5 mg/kg b.i.d. quinapril, and six dogs treated with 8 mg/kg q.d. minoxidil underwent 6 hours daily of hindquarter compression for 9 weeks. Minoxidil significantly decreased baseline blood pressure (-17 mm Hg; p less than or equal to 0.01), whereas quinapril decreased baseline blood pressure 11 mm Hg but not significantly (p = 0.15). Hindquarter compress...

BACKGROUND The variable success of topical minoxidil in the treatment of androgenic alopecia has led to the hypothesis that other pathways could mediate this form of hair loss, including infection and/or microinflammation of the hair follicles. In this study, we prepared a multimodal microemulsion comprising minoxidil (a dihydrotestosterone antagonist), diclofenac (a nonsteroidal anti-inflammat...

Minoxidil is a highly effective antihypertensive agent for patients with refractory hypertension. Long-term use of a high dose of minoxidil may cause several side effects. However, the concurrence of acute pulmonary edema and rapid progression of renal function after short-term and low-dose therapy is not common. Herein, we report the case of a 70-year-old woman who had diabetes mellitus and mi...

We examined uptake of the model therapeutic agent, minoxidil, into appendages, stratum corneum (SC), and through human skin, under the influence of different vehicles. Quantitative estimation of therapeutic drug deposition into all three areas has not previously been reported. Finite doses of minoxidil (2%, w/v) in formulations containing varying amounts of ethanol, propylene glycol (PG), and w...

Minoxidil is a strong arterial vasodilator used in the treatment of hypertension. In dermatology, topic minoxidil is widely used to treat hair fall. Hypertrichosis may occur if this form is misused. A 5 yearold girl developed patchy alopecia areata of the scalp. She was treated by minoxidil lotion 2% 10 times a day without medical prescription. Regrow of hair was rapidly obtained. However, the ...

BACKGROUND Two drugs which are approved for the treatment of androgenetic alopecia in women in Germany were compared with regard to their influence on hair growth. PATIENTS AND METHODS Patients were randomized to group I (n = 52) who used 2% minoxidil solution twice daily for a period of 12 months or to group II (n = 51) who used 0.025% alfatradiol solution once daily for 6 months and were th...